|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Current adjuvant treatment modalities for gastric cancer:From history to the future显示文摘The discrepancy between the surgical technique and the type of adjuvant chemotherapy used in clinical trials and patient outcomes in terms of overall survival rates has led to the generation of different adjuvant treatment protocols in distinct parts of the world.The adjuvant treatment recommendation is generally chemoradiotherapy in the United States,perioperative chemotherapy in the United Kingdom and parts of Europe,and chemotherapy in Asia.These options mainly rely on the United States Intergroup-0116,United Kingdom British Medical Research Council Adjuvant Gastric Infusional Chemotherapy,and the Asian Adjuvant Chemotherapy Trial of S-1 for Gastric Cancer and Capecitabine and Oxaliplatin Adjuvant Study in Stomach Cancer trials.However,the benefits were evident for only certain patients,which were not very homogeneous regarding the type of surgery,chemotherapy regimens,and stage of disease.Whether the dissimilarities in survival are attributable to surgical technique or intrinsic biological differences is a subject of debate.Regardless of the extent of surgery,multimodal therapy may offer modest survival advantage at least for diseases with lymph node involvement.Moreover,in the era of individualized treatment for most of the other cancer types,identification of special subgroups comprising those who will derive more or no benefit from adjuvant therapy merits further investigation.The aim of this review is to reveal the historical evolution and future reflections of adjuvant treatment modalities for resected gastric cancer patients. | Leyla Kilic Cetin Ordu Ibrahim Yildiz Fatma Sen Serkan Keskin Rumeysa Ciftci Kezban Nur Pilanci | 2016 | World Journal of Gastrointestinal Oncology2016，8，5： | 9 |
| 2 | Neoadjuvant hyperfractionated accelerated radiotherapy plus concomitant 5-fluorouracil infusion in locally advanced rectal cancer: A phase Ⅱ study显示文摘AIM To evaluate the efficacy and tolerability of neoadjuvant hyperfractionated accelerated radiotherapy(HART)and concurrent chemotherapy in patients with locally advanced infraperitoneal rectal cancer. METHODS A total of 30 patients with histopathologically confirmed T2-3/N0+ infraperitoneal adenocarcinoma of rectum cancer patients received preoperative 42 Gy/1.5 Gy/18 days/bid radiotherapy and continuous infusion of 5-fluorouracil(325 mg/m^2). All patients were operated 4-8 wk after neoadjuvant concomitant therapy. RESULTS In the early phase of treatment, 6 patients had grade Ⅲ-Ⅳ gastrointestinal toxicity, 2 patients had grade Ⅲ-Ⅳ hematologic toxicity, and 1 patient had grade Ⅴ toxicity due to postoperative sepsis during chemotherapy. Only 1 patient had radiotherapy-related late side effects, i.e., grade Ⅳ tenesmus. Complete pathological response was achieved in 6 patients(21%), while near-complete pathological response was obtained in 9(31%). After a median follow-up period of 60 mo, the local tumor control rate was 96.6%. In 13 patients, distant metastasis occurred. Disease-free survival rates at 2 and 5 years were 63.3% and 53%, and corresponding overall survival rates were 70% and 53.1%, respectively.CONCLUSION Although it has excellent local control and complete pathological response rates, neoadjuvant HART concurrent chemotherapy appears to not be a feasible treatment regimen in locally advanced rectal cancer, having high perioperative complication and intolerable side effects. Effects of reduced 5-fluorouracil dose or omission of chemotherapy with the aim of reducing toxicity may be examined in further studies. | Zeynep Gural Sezer Saglam Serap Yucel Esra Kaytan-Saglam Oktar Asoglu Cetin Ordu Hediye Acun Rasul Sharifov Semen Onder Ahmet Kizir Ethem N Oral | 2018 | World Journal of Gastrointestinal Oncology2018，10，1： | 3 |
| 3 | Reduced aerobic capacity in patients with severe osteoporosis: a cross sectional study显示文摘 | Ordu Gokkaya NK Koseoglu F Albayrak N | 2008 | Eur J Phys Rehabil Med2008，44，2： | 1 |
| 4 | Efficacy of short-term high-dose atorvastatin for prevention of contrast-induced nephropathy in patients undergoing coronary angiography显示文摘 | Ozhan H Erden I Ordu S | 2010 | Angiology2010，61，7： | 1 |
| 5 | Carbohydrate antigen- 125 and N-terminal pro-brain natriuretic peptide levels: compared in heart- failure prognostication 显示文摘 | Serkan Ordu Hakan Ozhan Recai Alemdar | 2012 | Texas Heart Institute2012，39，1： | 1 |
| 6 | Efficacy of short-term high-dose atorvastatin for prevention of contrast-induced nephropathy in patients undergoing coronary angiography显示文摘 | Ozhan H Erden I Ordu S | | 0，，07： | 1 |
| 7 | Degradation of free and sulfur-dioxide-bound acetaldehyde by malolactic lactic acid bacteria in white wine显示文摘 | Osborne J P DubéMorneau A Mira de Ordua R | 2006 | Journal of Applied Microbiology2006，，101： | 1 |
| 8 | Studies of floating dosage forms of furosemide: in vitro and in vivo evaluations of bilayer tablet formulations 显示文摘 | Ozdemir N Ordu S Ozkan Y | 2000 | Drug Dev Ind Pharm2000，26，8： | 1 |
| 9 | Efficacy of nebivolol on flow-mediated dilation in patients with slow coronary flow显示文摘 | Albayrak S Ordu S Yuksel S | 2009 | Int Heart J2009，50，： | 1 |
| 10 | The prognostic value of mean platelet volume in deeompensated heart failure 显示文摘 | Kandis H Ozhan H Ordu S | 2011 | Emerg Med J2011，28，： | 1 |
| 11 | Reduced aerobic capacity in patients with severe osteoporosis:a cross sectional study显示文摘 | Ordu Gokkaya NK Koseoglu F Albayrak N | 2008 | Eur J Phys Rehabil Med2008，44，2： | 1 |
| 12 | The prognostic value of mean plate-let volume in decompensated heart failure显示文摘 | Kandis H Ozhan H Ordu S | 2011 | Emerg Med2011，28，7： | 1 |
| 13 | A case of acute stent thrombosis treated successfully with intracoronary tirofiban显示文摘 | Erdenl Ozhan H Ordu S | 2010 | Kardiol Pol2010，68，4： | 1 |
| 14 | Does early PET/CT as- sesment of response to chemotherapy predicts survival in patients with advanced stage non-small-cell lung cancer 显示文摘 | Ordu C Selcuk NA Erdogan E | 2014 | Medicine2014，93，28： | 1 |
| 15 | Studies of floating dosage forms of furosemide:In vitro and in vivo evaluations of bilayer tablet formulations显示文摘 | O¨ZDEMIR N ORDU S O¨ZKAN Y | 2000 | Drug Dev Ind Pharm2000，26，8： | 1 |
| 16 | Hydatid Cyst of the Lung: Diagnosis and Treatment显示文摘 | Guillermo Ramos M.D. Ph.D. Antonio Ordu?a M.D. Mariano García-Yuste M.D | 2001 | World Journal of Surgery2001，，： | 1 |
| 17 | Improvement of β-cyclodextrin 显示文摘 | Nurten Ozdemir Sefika Ordu | 1998 | Drug Dev Ind Pharm1998，24，1： | 1 |
| 18 | Diversity of Bacillus thuringiensis strains from latin america with insecticidal activity against different mosquito species显示文摘 | IbarraJE Cristina del Rinco'n M Ordu'z S | 2003 | Appl Environ Microbiol2003，69，： | 1 |
| 19 | Efficiacy of short-term highdose atrovastatin for prevention of contrast-induced nephropathy in patients undergoing coronary angiogrophy显示文摘 | Ozham H Erden I Ordu S | 2010 | Angiology2010，61，7： | 1 |
| 20 | Effect of Thermal Annealing on Mid-Infrared Transmission in Semiconductor Alloy-Core Glass-Cladded Fibers显示文摘We report a study investigating the effects of thermal annealing on the optical properties of Si-Ge alloy-core silica-cladded fibers.Low temperature fiber draw was performed with a laboratory-made draw tower at 1760°C that minimizes impurity diffusion from cladding to the core.As a post-drawing process,Si-Ge core fibers were annealed in a box furnace to alter the core structure.Microstructural and optical properties of fibers were investigated,and transmission losses were measured as 28 dB/cm at 6.1μm.Numerical studies were performed to analyze the experimental results and to find the optimum structure for low loss semiconductor-core glass-cladded fibers. | Mustafa Ordu Jicheng Guo Ahmet E.Akosman Shyamsunder Erramilli Siddharth Ramachandran Soumendra N.Basu | 2020 | Advanced Fiber Materials2020，2，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员